synthesis storage release and reuptake of catecholamines

Noradrenaline does hang around in the cytoplasm unescorted, but generally speaking you need to keep your catecholamines in vesicles.

 The VMAT-2 protein (vesicular amine transporter) concentrates the catecholamines in the vesicles. It is promiscuous: i.e. it has equal affinity for dopamine, adrenaline, noradrenaline, serotonin and so forth.  VMAT-2 gets about 90% of the catecholamines into vesicles; the rest float about in the cytoplasm and get metabolized by mitochondrial MAO.

 The low  pH inside the vesicles causes the catecholamines to become trapped;

In the acidic environment they exist in their ionized water-soluble form, and thus cannot diffuse out

 These vesicles act as storage for all kinds of monoamines.  The VMAT-2 doesn’t care what it pumps.

If dopamine enters the vesicles, it gets converted to noradrenaline by dopamine beta-hydroxylase (dβH)

 Catecholamine exocytosis is a process mediated by a bunch of proteins which have little clinical relevance outside of being the targets for the botulinum toxin and the tetanus toxin.

These proteins are SNAP-25, syntaxin and synaptobrevin.

Botulinum and tetanus toxins are more famous for this very same effect but at the neuromuscular junction.

 Nobody quite knows precisely what mechanisms trigger the exocytosis of catecholamines at the nerve terminals, but it looks like it is something to do with calcium influx through voltage-gated N-type calcium channels.  They open when the action potential reaches the synapse. The calcium influx then activates the vesicle fusion proteins, and exocytosis results.

  Activation of presynaptic alpha-2 receptors inhibits the release of catecholamines .   The specific alpha-2  receptor subtypes which  act presynaptically are alpha-2A and alpha-2C

 Activation of presynaptic beta-2 receptors enhances the release of catecholamines .   

Activation of presynaptic A-1 adenosine receptors inhibits the release of catecholamines

 This whole business with presynaptic receptors comes down to cyclic AMP.
 If you increase cAMP (a β-2  effect), you enhance the release of catecholamines.

If you inhibit the production of cAMP (an α-2 or P1 adenosine receptor effect) the release of catecholamines will be decreased.

 Removal of catecholamines from the synapse is effected by the NET and DAT proteins (NorEpinephrine Transporter and DopAmine Transporter).  These make attractive drug targets.

The influence of drugs on catecholamine neurotransmission

A gigantic diagram says a thousand words.

drugs acting on the synthesis storage release and reuptake of catecholamines.JPG"

Tyrosine metabolism

α-Methyltyrosine blocks the conversion of tyrosine into L-DOPA, which is a rate-limiting step. This is one way of treating phaeochromocytoma.

L-Dopa Metabolism

α-Methyldopa blocks  the conversion of L-DOPA into dopamine, and its active metabolite α-Methylnorepinephrine  is an alpha-2 receptor agonist, which is functionally similar to clonidine.

Interference with storage

Reserpine blocks VMAT-2, and can thus result in the depletion of catecholamines from all your nerve endings

Interference with the mechanisms of exocytosis

Botulinum and tetanus toxins proteolyse the fusion proteins, synaptobrevin specifically,   and thus prevent release of catecholamines and  acetylcholine

Inhibition of exocytosis

Clonidine and dexmedetomidine act here to inhibit release of catecholamines.
Ditto α-Methylnorepinephrine as mentioned above.

Stimulation of exocytosis

Xanthines like caffeine act as adenosine antagonists; they inhibit the inhibition. The net result is an enhanced release of catecholamines.

Interference with synaptic concentration

Indirect sympathomimetics act here by displacing catecholamines out of the synapse and into the extracellular fluid.

Inhibition of reuptake

Cocaine and the tricyclic antidepressants act at the NAT and DAT channels to decrease reuptake of noradrenaline, thus increasing its synaptic dwell-time.

Reversal of reuptake channels

Amphetamines also cause DAT and NET dysfunction, by causing internalization of the DAT protein, and by causing it to malfunction and actually leak dopamine back into the synapse

References

For this sort of really basic stuff, no matter where you look you will find essentially the same information.


I used chapters from "Goodman & Gilman's The Pharmacological Basis of Therapeutics" 11th ed by Brunton et al, and "Basic & Clinical Pharmacology" 11th ed. By Katzung et al.

I also perused Peck and Hill "Pharmacology for Anaesthesia and Intensive care" as well as the notoriously error-prone "Handbook of Pharmacology and Physiology in Anaesthetic Practice" by Stoelting and Hillier. Neither covered this subject in a depth I found satisfying.

Goodman and Gilman's remains a canonical text.